Officer Patrick Finn Files Intent to Sell $3.56M in Stock Amidst 52-Week Highs
TWST has more than doubled off its 52-week low of $23.3.
Summary
Officer Patrick Finn has filed a Form 144 to sell approximately $3.56 million worth of common stock, continuing a trend of insider sales while the stock trades near its 52-week high.
Key Events · Ownership and Investor Activity · TWST
-
Officer Files Intent to Sell
Officer Patrick Finn has filed a Form 144, indicating a proposed sale of 68,967 shares of common stock.
-
Significant Proposed Sale Value
The aggregate market value of the shares intended to be sold is approximately $3,562,414.66.
-
Follows Recent Insider Sales
This filing follows previous sales by Patrick Finn totaling $1,474,907.42 over the past three months, including a Form 144 filed on February 13, 2026, indicating a pattern of insider distribution.
-
Timing Near 52-Week Highs
The intent to sell comes as Twist Bioscience's stock is trading near its 52-week high, potentially signaling an effort to realize gains.
Analysis · TWST · Life Sciences
Officer Patrick Finn's filing of a Form 144 indicates an intent to sell a significant block of shares, valued at over $3.5 million. This proposed sale, following other recent dispositions by the same officer, suggests a pattern of insider selling. The timing is notable as the company's stock is currently trading near its 52-week high, which could imply the officer is locking in gains. Investors should monitor subsequent Form 4 filings to confirm the actual execution of these sales and assess the ongoing insider sentiment.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.6% of the 1725 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TWST was trading at $52.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $23.30 to $53.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.